Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (January 2024)
44 slides from Evogene's investor presentation, Jan 9, 2024
Slide 1: Company Presentation January 10, 2024
COMPANYpresentation January 10, 2024 Ofer Haviv, President & CEO
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of simi
Slide 3: Agenda
Agenda 3 About Evogene Annex I - Financial overview Annex II - Evogene subsidiaries Success Stories Business Model Summary
Slide 4: Our Vision: Decoding Biology
Our Vision 4 DECODING BIOLOGY Revolutionize the development of life-science based products, utilizing cutting edge computational biology technologies
Slide 5: Life Science Product Development – Current State
Life Science Product Development – Current State 5 Pharma Industry Ag-chemicalsIndustry Cost of developing a single pharmaceutical drug Years to develop a new crop protection product *https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-oth
Slide 6: The Ultimate Case of Finding the Needle in the Haystack
The Ultimate Case of Finding the “Needle in the Haystack” 6 The challenge: finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach successful products Agriculture Pharma Discovery Optimization Development Regulation ApprovedProduc
Slide 7: The Opportunity
Utilizing advanced computational biology technologies to discover and optimize the most promising candidates addressing multiple development challenges towards successful life-science based products The Opportunity PHARMA & WELLNESS AGRICULTURE & FOOD Other Industries Increase probability of success
Slide 8: Our Solution Platform
Our Solution 8 platform Incorporating deep scientific understanding with big data and advanced AI technologies, to successfully discover & guide the optimization of novel life-science based products – Computational Predictive Biology BIG DATA BIOLOGY AI When Biology MeetsDisruptive Technologies
Slide 9: Tailored AI Tech-Engines
Tailored AI Tech-Engines 9 The CPB platform directs and accelerates product discovery and optimization through dedicated AI Tech-Engines for products based on three core components: Microbes Small molecules Genetic elements MICROBES GENETIC ELEMENTS SMALL MOLECULES
Slide 10: AI Tech-Engines to Direct & Accelerate Product Discovery & Optimization
AI Tech-Engines to direct & accelerate product discovery & optimization 10 Discovery Computational selection of the most promising candidates to initiate the product development process. Optimization Computational driven solution addressing optimization challenges for the selected candidates, withou
Slide 11: AI Tech-Engine Dashboard (Example)
AI Tech-EngineDashboard(Example) 11
Slide 12: Potential Market Diversity
Potential Market Diversity 12 AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES PlasticDegradation Chemicals Source forEnzymes Oil SpillClearing WastewaterTreatments Microbialsfor Crops Food Human &Animal Probiotics Therapeuticmicrobials Probiotics DietarySupplements Structuring an ’ecosystem’ o
Slide 13: Agenda
Agenda 13 Annex I – Financial overview Annex II – Evogene subsidiaries About Evogene Success Stories Business Model Summary
Slide 14: Evogene's AI Tech-Engines - Potential Markets
Evogene’s AI Tech-Engines - Potential Markets 14 AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Plasticdegradation Chemicals Source forenzymes Oil spillclearing Waste-watertreatments Microbialsfor crops Food Human &animal probiotics Therapeuticmicrobials Probiotics Dietarysupplements Cropprot
Slide 15: Business Strategy
Business Strategy 15 Capture the value of our AI tech-engines as product-development enablers, through two types of business models: Joint product development with leading companies utilizing Evogene’s unique tech-engines. Typically, the partner leads later-stage development and product commercializ
Slide 16: Licensing | Business Model
16 Licensing 1 | Business Model Licensing Evogene’s AI Tech-Engines to a third party (currently, all Evogene subsidiaries) Potential revenue stream License fees & R&D reimbursement Dividends to Evogene as a shareholder Significant one-time-payment upon an exit event* Powered by: *As long as Evogene
Slide 17: Collaboration | Business Model
Collaboration 2 | Business Model 17 Collaborations Driven by Evogene’s AI Tech-Engines with Leading Life-Science Companies Potential revenue stream Upfront payments R&D fees Milestone payments Royalties from sale of end-products Powered by:
Slide 18: Licensing & Collaboration - Current Status
Aquaculture Licensing & Collaboration - Current Status 18 AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES AGRICULTURE & FOOD OTHER INDUSTRIES PHARMA AGRICULTURE & FOOD PHARMA OTHER INDUSTRIES Licensing / Subsidiaries Collaboration MICROBES GENETIC ELEMENTS SMALL MOLECULES Medical Cannabis Impr
Slide 19: Agenda
Agenda 19 Annex I – Financial overview Annex II – Evogene subsidiaries Success Stories Business Model Summary About Evogene
Slide 20: Evogene's Subsidiary Lavie Bio
Evogene’s Subsidiary Mission Improve food quality, sustainability and agricultural productivitythrough microbiome-based, ag-biological products 20 Ag-biologicals a rapidly growingmarket Unique AI tech-platform and data assets Broad &diversepipeline 8 programs –new product launch expected every 1-2 y
Slide 21: Subsidiary Yalos - Bio-inoculant for Cereal Grains
Evogene’s Subsidiary Yalos™ - Bio-inoculant for cereal grains* Sold in USA**& expanding globally Superior performancevs. alternatives Consistent performance providing farmers 4:1 ROI Check 2% 1% 3% 4% 6% Other Ag-biologicals Control Yield improvement (%) 5% * Yalos™ has regulatory approval in the US
Slide 22: Subsidiary MicroBoost AI Tech-Engine
Evogene’s Subsidiary MicroBoost AI tech-engine directing & accelerating product discovery & optimization Powered by Computational analysis of DB ~100,000 Bacterialstrains 1,000 Predicted bacterial strains 50 Validated bacterialstrains 10 Predicted teams Powered by Experimental validation 5% success
Slide 23: LAV311 - Bio-pesticide for Fruit Rots & Powdery Mildew
* Evogene’s Subsidiary LAV311 - Bio-pesticide for Fruit rots & Powdery mildew Licensing agreement with $5M upfront payment Future milestone payments Royalties from future sales Superior performance compared to competing biological control products, similar results to chemicals Consistent performance
Slide 24: Subsidiary MicroBoost AI Tech-Engine
Evogene’s Subsidiary MicroBoost AI tech-engine directing & accelerating product discovery & optimization Powered by Increaseprobability of success Reducetime and cost 24 400 Bacterial strains 60 Bacterial strains 7 Strains Computational machine learning Powered by Experimental validation 15% success
Slide 25: Evogene's Subsidiary Casterra
Evogene’s Subsidiary Mission Provide elite castor seeds to the bio-based industries 25 Castor oil - emerging market Holistic ag-solution 3 Commercial revenue generating castor varieties Proprietary varieties with improved traits suitable for commercial scale cultivation EVF716, EVF712, EVF701 Propri
Slide 26: Elite Castor Varieties EVF716, EVF712, EVF701
Evogene’s Subsidiary EVF716, EVF712, EVF701 Elite Castor Varieties 26 Powered by * Variety performance is subjected to weather conditions and to precipitation
Slide 27: Castor Seed Sales
Evogene’s Subsidiary Castor Seed Sales 27 Powered by * Variety performance is subjected to weather conditions and to precipitation $2.2 Million $9.1 Million
Slide 28: GeneRator AI Tech Engine
Evogene’s Subsidiary GeneRator AI tech enginedirecting & accelerating product discovery & optimization 28 Powered by * Variety performance is subjected to weather conditions and to precipitation Genetic diversity ~200 * WW germplasm accessions >10,000 Lines 800 Lines w/ high yield & oil potential 15
Slide 29: Agenda
Agenda 29 Annex I – Financial overview Annex II – Evogene subsidiaries Business Model Summary About Evogene Success Stories
Slide 30: The Evogene Group
30 As of Nov 13, 2023 142 Employees 29 % PhDs 50 % Women TheEvogene Group (98%*) (100%*) (100%*) (70%*) (76%*) *Evogene holdings
Slide 31: Summary
Our vision 31 Revolutionize the development of life-science based products, utilizing cutting edge computational biology technologies Our unique offering - 3 AI Tech-Engines to direct & accelerate product discovery and optimization: MicroBoost AI ChemPass AI GeneRator AI Current subsidiaries Biomica
Slide 32: Thank You
THANK evOgene
Slide 33: Annex I: Financial Overview
Annex I:Financial Overview 33
Slide 34: Key Financials: Balance Sheet
Key Financials:Balance Sheet Key Points: Consolidated cash position: ~$37 million as of 30.09.2023 This Consolidated cash position does not include the $2.5 million, which represents the second half of the upfront payment from the licensing agreement of Lavie Bio with Corteva and amount due to the p
Slide 35: Annex II: Evogene Subsidiaries
Annex II:Evogene Subsidiaries 35
Slide 36: Evogene Subsidiaries
*Evogene holdings **Includes $10M cash investment along with transfer of assets Microbiome-basedTherapeutics Immuno-oncology GI- related disorders Ag Biologicals Bio-stimulants Bio-pesticides 76%* 70%* Ag Chemicals Herbicides Fungicides Insecticides Medical Cannabis High yield & consumer traits Ther
Slide 37: Products & Pipeline | Human Microbiome
37 Immuno-oncology program Combination therapy for cancer with checkpoint inhibitors Phase 1 clinical stage Addressable market of $309.7B (by 2030*) GI related disorders Inflammatory Bowel Disorder (IBD) – pre-clinical stage Irritable Bowel Syndrome (IBS) – pre-clinical stage Addressable market: IBD
Slide 38: Immuno-Oncology Program – BMC128 Example Results
38 Example Results: Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo | Human Microbiome Powered by
Slide 39: Products & Pipeline | Ag-Biologicals
39 | Ag-Biologicals Bio-stimulants Yalos™ – primarily spring wheat: commercial stage; addressable USA & Canada markets ~25M acres* Bio-stimulants #2 – primarily soy: pre-development stage; addressable market ~90M acres* Bio-pesticides Fruit rots – primarily grapes: pre-commercial; addressable market
Slide 40: Ag-Biologicals Example Results
40 | Ag-Biologicals Example of treatment against Botrytis Cinerea vs untreated control in vines Lavie Bio’s wheat field in the USA during harvest – Sales initiated in 2022 Example Results: - Yalos™ inoculant for spring wheat - LAV 311 bio-fungicide candidates for fruit rot LAV311 Powered by License
Slide 41: Products & Pipeline | Ag-Chemicals
41 Products & Pipeline | Ag-Chemicals Expected upcoming value drivers Powered by Mission:Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology Herbicides Novel Mode-of-Action selective herbicide Herbicides addressable market – $48.
Slide 42: Ag-Chemicals Example Results: APH1 Herbicide
42 Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 | Ag-Chemicals Greenhouse testing of APH1 – Conferring resistance by modifying tobacco (weed) Example Results: New MoA Herbicide – APH1 Powered by
Slide 43: Product & Pipeline | Biobased Materials
43 | Biobased Materials Powered by Product & Pipeline Expected upcoming value drivers Mission:Leading the castor oil market with an integrated solution for industrialized cultivation of castor in support of the biobased materials industry Elite castor seed varieties ‘EVF’ series - castor seed suitab
Slide 44: High Yield & Oil Castor Seeds
44 High Yield & Oil Castor Seeds Dedicated machinery | Biobased Materials Powered by Mechanical Harvest Proprietary dehulling machine Castor growth protocol Elite castor seed varieties – The ‘EVF’ series EVF701 EVF716 EVF712